Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

New diagnostic and therapeutic medical technology based on the autonomic nervous system and physiological systems of the brain.

Country of Origin: United Kingdom
Reference Number: TOUK20160119001
Publication Date: 20 January 2016

Summary

A UK SME has developed the first medical technology which is based upon an understanding of how the brain regulates the body’s function i.e. the autonomic nervous system and physiological systems; which is able to apply such knowledge with diagnostic and therapeutic effect; and which appears to comply with the key aims and objectives of the EC’s Human Brain Project. Academic, research or clinical partners are sought to validate the technology via research collaboration agreements.

Description

An innovative UK SME has developed a new medical technology which builds on an understanding of how the brain regulates the body’s function and which appears to comply with the key aims and objectives of the EC’s Human Brain Project.

It is a cognitive, computer-based, games-like technology which is based upon an original mathematical model of the autonomic nervous system and physiological systems. It is the first technology to link cognition to cellular & molecular biology. It does so because proteins absorb and emit light as they react i.e. the emitted bioluminescence alters our colour perception. The consequences of this technology are both diagnostic and therapeutic i.e. (i) to link deficiencies in the spectrum of colour perception to the onset of pathologies and (ii) to provide colour supplements in the form of a biofeedback light therapy.

The technology is incorporated into a cognitive test which is conducted on most common lap-tops. It requires the patient to study and memorise the colours in a video which is displayed for 15 seconds. At the end of this period a colour filter is imposed. The task for the patient is to use the ‘mouse’ to select colours from the displayed colour palette and to recover the colour balance of the original video. This provides the data which the mathematical program requires in order to compute the health of the patient.

If therapy is required, the mathematics of the program compute the parameters of a unique light/bioresonant/biofeedback type informational/corrective therapy. This program is provided to the patient who installs it in their home PC. Their task being to watch the contents of the screen for two 20 minute sessions each day.

The technology is able to determine the full range of pathologies in the patient. This is especially significant because most medical conditions are complex, multi-systemic and multi-pathological i.e. there are few medical conditions which can accurately be determined by a single pathological process. It compares favourably with biomarker-type techniques which have a range of inherent limitations, which determine only a single identified pathological process, and which are often significantly inaccurate. It also compares with genetic screening which can only determine the genetic component of a medical condition and which ignores the significant influence of phenotype.

The UK company is offering the technology to potential partners as part of its program to commercialise the technology in all world markets. This requires that the technology be further validated by independent experts who are able to evaluate, validate and comment upon the technique developed, and also by clinicians who are able to compare and/or validate the ability of the technology to diagnose and/or treat patients. The initial focus for validation will be in the medical area of diabetes.

The company therefore seeks the cooperation of (i) an academic or research-based enterprise which can, collaboratively or independently, validate the scientific basis for the technology and (ii) clinicians and/or a clinical research organisation which can, collaboratively or independently, validate the claims made for this unique technology. It is envisaged that partnerships will be achieved via research collaboration agreements.

Advantages and Innovations

The technology is based upon the observation that sensory input, in particular colour perception, has pathological correlates. This has led to the development of a unique method of screening the health of the patient e.g.

- To be able to determine the onset of pathologies from their presymptomatic onset;
- To distinguish between the genotype and phenotype of every pathology;
- To determine typically 5-15 pathological indications in each organ (in around 30 organs) including many for which there is currently an unmet clinical need or where better tests are required;
- To determine the most destabilised physiological systems in the patient;
- To do so in a 20 minute non-invasive cognitive test;
- At a level of cost which is estimated to be typically 5-10 times lower than current diagnostic or screening technologies;
- Providing improved quality of life.

Initial in-market surveillance has indicated the technology to be capable of determining the health of the patient at a level which is indicatively 2-23% more accurate than the complete range of diagnostic tests which were in routine use in the various medical clinics and against which the technology was compared.

Additionally, using the data derived from the cognitive test the mathematics of the program determines the parameters for a form of biofeedback which, initial in-market feedback has shown to be about 83-96% effective with regard to the treatment of around 30 common categories of medical conditions.

The technology is relatively simple to use and requires training of typically 1-2 days. Independent reports have indicated the potential of the technology to significantly reduce the cost of diagnosing and treating diabetes, however the technology is not limited to diabetes. The main value of the technology is to diagnose the range of emergent co-morbidities, which could lead to substantial potential cost-savings arising from the use of this technology within the EC.

Stage Of Development

Already on the market

Stage Of Development Comment

The technology is available in its commercial form although the company accepts that it could be possible to unbundle the technology into specific applications which could serve specific markets and/or to further develop the technology.

Requested partner

The company seeks research cooperation partners who are able to validate this technology, and they are likely to be from clinical research organisations and/or academia and should include medical statisticians who are able to compile and process the large amounts of data into a publishable form.

The initial focus of the company is to validate the technology in the medical area of diabetes. Diabetes has been selected because the technology offers specific benefits by comparison with current techniques and also that it is widely recognised that there is a need for a better test to distinguish between pre-diabetes and diabetes; and to determine whether the condition is type 1, type 2 or a combination of both; to determine the onset and progression of diabetic co-morbidities e.g. cardiovascular disease, kidney disease, pancreatic cancer, prostate cancer, Alzheimer’s disease, etc.; and to better understand the etiology associated with ‘regulation of blood glucose’.

Accordingly the partner(s) should have access to clinical expertise which can undertake the required level of such testing.

In addition, the company is also open to engaging with organisations who may be interested in collaborating on Horizon 2020 grant applications.

Kooperationsanfrage stellen